Kyverna Therapeutics (KYTX) Jefferies London Healthcare Conference 2025 summary

Strategic vision and clinical progress

• Focused on pioneering CAR T therapies for autoimmune diseases, with KYV-101 designed for improved safety and efficacy.

• Over 100 patients treated across multiple autoimmune indications, showing no high-grade CRS or ICANS and strong early efficacy.

• First-mover advantage targeted in stiff person syndrome (SPS) and myasthenia gravis (MG), with clear FDA pathways and pivotal studies underway.

• Next-generation KYV-102 aims to broaden patient access and reduce manufacturing costs.

• Early data in MS and RA indicate potential for expansion into larger patient populations.

Clinical outcomes and differentiation

• KYV-101 achieves deep B-cell depletion, enabling long-term, drug-free remission in SPS and MG.

• Early SPS patients showed over 50% improvement in 25-foot walk test and elimination of background therapies.

• MG interim phase 2 results: 100% response rate, 67% reaching minimal symptom expression, and all patients off background immunosuppressants.

• Safety profile remains consistent across over 100 patients dosed.

• Early MS and RA data show all MS patients stable or improved, and significant ACR responses in RA.

Market opportunity and commercialization

• SPS market estimated at 6,000 diagnosed US patients, with 2,000–2,500 severely refractory and addressable initially.

• MG market much larger, with up to 40,000 patients inadequately controlled by current therapies.

• High annual costs for current therapies highlight economic value of a one-time CAR T treatment.

• Commercial infrastructure and payer strategies being developed to leverage first-mover status.

• Cash runway extends into 2027, supported by recent debt financing.